NF1 mutation rather than individual genetic variability is the main determinant of the NF1-transcriptional profile of mutations affecting splicing

被引:20
作者
Pros, Eva
Larriba, Sara
Lopez, Eva
Ravella, Anna
Lluisa Gili, M.
Kruyer, Helena
Valls, Joan
Serra, Eduard
Lazaro, Conxi
机构
[1] Hosp Duran & Reynals, Ctr Genet Med & Mol, IRO, IDIBELL,Ctr Genet Med & Mol, Lhospitalet De Llobregat 08907, Spain
[2] Hosp Creu Roja De Barcelona, Serv Dermatol, Barcelona, Spain
[3] Hosp Duran & Reynals, Ctr Genet Med & Mol, IRO, IDIBELL,Unitat Bioinformat & Bioestadist, Lhospitalet De Llobregat 08907, Spain
关键词
NF1; exon skipping; splicing; transcriptional profile;
D O I
10.1002/humu.20396
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
A significant number of neurofibromatosis type 1 (NF1) mutations result in exon skipping. The majority of these mutations do not occur in the canonical splice sites and can produce different aberrant transcripts whose proportions have not been well studied. It has been hypothesized that differences in the mutation, determined NF1-transcriptional profile could partially explain disease variability among patients bearing the same NF1 splice defect. In order to gain insight into these aspects, we analyzed the proportion of the different transcripts generated by nine NF1-splicing mutations in 30 patients. We assessed the influence of the mutation in the NF1-related transcriptional profiles and investigated the existence of individual differences in a global manner. We analyzed potential differences in tissue-specific transcriptional profiles and evaluated the influence of sample processing and mRNA nonsense-mediated decay (NMD). Small transcriptional differences were found in neurofibromas and neurofibroma-derived Schwann cells (SC) compared to blood. We also detected a higher cell culture-dependent NMD. We observed that mutation per se explains 93.5% of the profile variability among mutations studied. However, despite the importance of mutation in determining the proportion of NF1 transcripts generated, we found certain variability among patients with the same mutation. From our results, it seems that genetic factors influencing RNA processing play a minor role in determining the NF1-transcriptional profile. Nevertheless neurofibromin studies would clarify whether these small differences translate into significant functional changes that could explain the great clinical expressivity observed in the disease or any of the disease-related traits.
引用
收藏
页码:1104 / 1114
页数:11
相关论文
共 55 条
[1]   A CONSERVED ALTERNATIVE SPLICE IN THE VONRECKLINGHAUSEN NEUROFIBROMATOSIS (NF1) GENE PRODUCES 2 NEUROFIBROMIN ISOFORMS, BOTH OF WHICH HAVE GTPASE-ACTIVATING PROTEIN-ACTIVITY [J].
ANDERSEN, LB ;
BALLESTER, R ;
MARCHUK, DA ;
CHANG, E ;
GUTMANN, DH ;
SAULINO, AM ;
CAMONIS, J ;
WIGLER, M ;
COLLINS, FS .
MOLECULAR AND CELLULAR BIOLOGY, 1993, 13 (01) :487-495
[2]   Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients [J].
Andreassi, C ;
Jarecki, J ;
Zhou, JH ;
Coovert, DD ;
Monani, UR ;
Chen, XC ;
Whitney, M ;
Pollok, B ;
Zhang, ML ;
Androphy, E ;
Burghes, AHM .
HUMAN MOLECULAR GENETICS, 2001, 10 (24) :2841-2849
[3]  
AndreuttiZaugg C, 1997, CANCER RES, V57, P3288
[4]   Recurrent mutations in the NF1 gene are common among neurofibromatosis type 1 patients -: art. no. e82 [J].
Ars, E ;
Kruyer, H ;
Morell, M ;
Pros, E ;
Serra, E ;
Ravella, A ;
Estivill, X ;
Lázaro, C .
JOURNAL OF MEDICAL GENETICS, 2003, 40 (06) :e82
[5]   Mutations affecting mRNA splicing are the most common molecular defects in patients with neurofibromatosis type 1 [J].
Ars, E ;
Serra, E ;
García, J ;
Kruyer, H ;
Gaona, A ;
Lázaro, C ;
Estivill, X .
HUMAN MOLECULAR GENETICS, 2000, 9 (02) :237-247
[6]   Cold shock induces the insertion of a cryptic exon in the neurofibromatosis type 1 (NF1) mRNA [J].
Ars, E ;
Serra, E ;
de la Luna, S ;
Estivill, X ;
Lázaro, C .
NUCLEIC ACIDS RESEARCH, 2000, 28 (06) :1307-1312
[7]   Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy [J].
Brichta, L ;
Hofmann, Y ;
Hahnen, E ;
Siebzehnrubl, FA ;
Raschke, H ;
Blumcke, I ;
Eyupoglu, IY ;
Wirth, B .
HUMAN MOLECULAR GENETICS, 2003, 12 (19) :2481-2489
[8]   Listening to silence and understanding nonsense: Exonic mutations that affect splicing [J].
Cartegni, L ;
Chew, SL ;
Krainer, AR .
NATURE REVIEWS GENETICS, 2002, 3 (04) :285-298
[9]   A MAJOR SEGMENT OF THE NEUROFIBROMATOSIS TYPE-1 GENE - CDNA SEQUENCE, GENOMIC STRUCTURE, AND POINT MUTATIONS [J].
CAWTHON, RM ;
WEISS, R ;
XU, GF ;
VISKOCHIL, D ;
CULVER, M ;
STEVENS, J ;
ROBERTSON, M ;
DUNN, D ;
GESTELAND, R ;
OCONNELL, P ;
WHITE, R .
CELL, 1990, 62 (01) :193-201
[10]   Treatment of spinal muscular atrophy by sodium butyrate [J].
Chang, JG ;
Hsieh-Li, HM ;
Jong, YJ ;
Wang, NM ;
Tsai, CH ;
Li, H .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (17) :9808-9813